COVID-19 vaccine effectiveness

If you want to see all comparisons, please click here

EpiVacCorona vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots

Evidence profile

Summary of findings


Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04527575
EpiVac LLC ; State Scientific Center of Virology and Biotechnology “Vector” of Rospotrebnadzor
Ryzhikov AB, Infektsiia Immun, 2021

Full text
Commentary
Protein subunit

EpiVacCorona

Placebo

RCT
Phase 2
Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia. N=86
Some concerns
Details

Full description

For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.